Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

This study is currently recruiting participants.

The purpose of this study is to test the safety of a study drug called duvelisib.

Study Type:  Interventional

Study Design:  

Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Conditions:  

Lymphoma
Relapsed/Refractory T-cell Lymphomas

Interventions:  

Drug: Romidepsin
Drug: Bortezomib
Drug: Duvelisib

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/NCT02783625